Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30435500 | 1.00 | BTN3A1 (0.42) | BTN3A1ELANECASP1MAPTALDH1A1 | |
| SCHEMBL22065060 | 1.00 | BTN3A1 (0.42) | BTN3A1ELANECASP1MAPTALDH1A1 | |
| SCHEMBL20833545 | 1.00 | BTN3A1 (0.42) | BTN3A1ELANECASP1MAPTALDH1A1 | |
| SCHEMBL22066284 | 0.92 | BTN3A1 (0.42) | BTN3A1ELANECASP1MAPTALDH1A1 | |
| SCHEMBL24793363 | 0.90 | BTN3A1 (0.43) | BTN3A1ELANECASP1MAPTALDH1A1 | |
| SCHEMBL28986476 | 0.89 | BTN3A1 (0.41) | BTN3A1ELANEALDH1A1KDM4ELMNA | |
| SCHEMBL29895522 | 0.89 | BTN3A1 (0.41) | BTN3A1ELANEALDH1A1KDM4ELMNA | |
| SCHEMBL22065039 | 0.89 | BTN3A1 (0.51) | BTN3A1ELANECASP1MAPTALDH1A1 | |
| SCHEMBL24794260 | 0.88 | BTN3A1 (0.42) | BTN3A1ELANECASP1MAPTALDH1A1 | |
| SCHEMBL22065801 | 0.88 | BTN3A1 (0.42) | BTN3A1ELANECASP1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171487-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2025-05-29 | — | — | US | disclosed |
| EP-3684780-B1 | FLOXURIDINE SYNTHESIS | NuCana plc (GB) | 2024-05-29 | — | — | EP | disclosed |
| US-11414451-B2 | Floxuridine synthesis | NuCana plc (GB) | 2022-08-16 | — | — | US | disclosed |
| US-11414452-B2 | Synthesis of phosphate derivatives | NuCana plc (GB) | 2022-08-16 | — | — | US | disclosed |
| US-20200262859-A1 | FLOXURIDINE SYNTHESIS | NuCana plc (GB) | 2020-08-20 | — | — | US | disclosed |
| EP-3684780-A1 | FLOXURIDINE SYNTHESIS | Nucana PLC (GB) | 2020-07-29 | — | — | EP | disclosed |
| WO-2020128469-A1 | SYNTHESIS OF 8-CHLOROADENOSINE DERIVATIVES INCLUDING NUC-9701 | NuCana plc (GB) | 2020-06-25 | — | — | WO | disclosed |
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
| EP-3638684-A2 | SYNTHESIS OF SUBSTANTIALLY DIASTEREOMERICALLY PURE PHOSPHATE PROTIDES | NuCana plc (GB) | 2020-04-22 | — | — | EP | disclosed |
| WO-2019053476-A1 | FLOXURIDINE SYNTHESIS | NuCana plc (GB) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019053476-A1 | FLOXURIDINE SYNTHESIS | NuCana plc (GB) | 2019-03-21 | — | — | WO | disclosed |
| WO-2018229493-A2 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2018-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414452-B2 | Synthesis of phosphate derivatives | PNP, NTPCR, TYMP | BTN3A1 2937/4885ELANE 3910/4885CASP1 3511/4885 |
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PPA1, PPIP5K2, TYMP | BTN3A1 4531/4885ELANE 4653/4885CASP1 4061/4885 |
| US-11414451-B2 | Floxuridine synthesis | DUT, UMPS, TYMS | BTN3A1 2998/4885ELANE 3811/4885CASP1 4307/4885 |
| US-20250171487-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PNP, NTPCR, TYMP | BTN3A1 2948/4885ELANE 3870/4885CASP1 3460/4885 |
| US-20200262859-A1 | FLOXURIDINE SYNTHESIS | DUT, UMPS, TYMS | BTN3A1 2998/4885ELANE 3811/4885CASP1 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.